Brightgene Bio-Medical Technology Co. Ltd. has patented new calcitonin receptor (CALCR; CT-R) and amylin AMY3 receptor agonists potentially useful for the treatment of obesity and metabolic disorders.
Amylin is a hormone co-secreted with insulin in the pancreas that has anorexigenic effects, since it promotes satiety and reduces food intake. Amylin analogs and dual agonists of the amylin and calcitonin receptors have been developed for treating obesity. Astrazeneca plc reported results with their AMYR3 agonist AZD-6234.
